Trial results

Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

NCT07610174 on ClinicalTrials.gov · last registry update 2026-05-29

Finished 29 April 2026, after enrolling 160 people. Primary outcome, as filed: Change from Baseline in Left Ventricular Global Longitudinal Strain (LV-GLS) assessed by echocardiography. semaglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Kafrelsheikh University

Sponsor type

Other

Enrollment

160

Started

2025-06-02

Primary completion

2026-04-29 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in Left Ventricular Global Longitudinal Strain (LV-GLS) assessed by echocardiography

Conditions studied

Heart Failure · Heart Valve Prosthesis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.